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Provision of healthcare for head and neck cancer 
patients presents a particular challenge because of the 
complexity of the anatomical structures and functions 
affected, the variety of professional disciplines 
involved in caring for patients, and the specialised 
forms of therapy and support required in the various 
stages of management (1).  There are over 30 specific 
sites (ICD10 codes) categorised under head and neck 
cancer, and co-morbidities such as respiratory or 
cardio-vascular conditions are common (2).  Over 
90% of malignancies occurring in the head and neck 
are squamous cell carcinomas (HNSCC) (3).  
 In this issue of the journal, Solomon et al 
(4), examines the negative impact of treatment 
interruptions on one of the modalities of head and neck 
cancer treatment, namely radiotherapy.  In addition to 
radiation morbidity, external factors such as financial 
difficulties, transport problems and negative attitudes 
towards radiotherapy are known to adversely influence 
the continuity of patients’ treatment. Technical issues 
such as mechanical breakdowns and inefficient 
procurement systems also contribute to unscheduled 
treatment interruptions, particularly in developing 
countries where radiotherapists often provide services 
in resource-limited situations (4, 5, 6). 
 Radiotherapy is a well established mode 
of therapy for HNSCC, either as an adjuvant to 
surgery and chemotherapy or as the main treatment 
option.  However, treatment interruption and early 
discontinuation raises the possibility of recurrent 
disease which may in some cases be more aggressive 
than the primary condition (7, 8).  Increased tumour 
aggression after the commencement of radiotherapy 
has been attributed to rapid repopulation of the 
malignancy by means of accelerated proliferation 
of tumour stem cells (9).    
 The options of altered fractionation regimens, 
synchronous chemoradiation and 3D conformal 
treatment were designed to minimize occurrence 
of complications during the irradiation of local or 
regional lesions. In centres where these alternatives 
are not available, radiation-associated morbidity is a 
frequent cause of treatment interruptions in patients 
undergoing treatment for head and neck cancers (10). 
Solomon and co-authors provide a critical evaluation of 
patients undergoing radical radiotherapy at Kenyatta 
National Hospital, reporting that the most important 
common cause of treatment interruption and/ or 
discontinuation is indeed radiation morbidity (4).  
 The paper does not however investigate the 
factors that contribute to this situation in the national 
referral hospital.  A report of frequent and prolonged 
treatment interruptions among patients undergoing 
radiotherapy at a tertiary healthcare institution 
has significant implications for the management 
of all radiosensitive cancers. Further research and 
consultation is urgently needed so as to develop 
evidence-based methods of improving treatment 
compliance by reducing the frequency and severity 
of the side effects.
 Pre-treatment assessment of the HNSCC patient 
requires a specialised diagnostic sequence, with 
imaging techniques and pathological assessment 
used as an integral part of diagnosis and staging 
of the cancer.  Treatment modalities are mainly 
determined by the clinical stage of the disease, the 
site of the primary lesion and the general health of 
the patient.  The cost of this comprehensive medical 
care is prohibitive to most patients, causing many 
to seek treatment when the cancer is at an advanced 
stage.  Management of a more aggressive TNM Stage 
3 or Stage 4 malignancy implies a poorer prognosis, 
and is bound to cause further strain on the healthcare 
limited resources. 
 The issue of lack of expertise also contributes 
to the poor prognosis for HNSCC.  A complete 
multidisciplinary team for management of head 
and neck cancers includes a diverse group of experts 
including maxillofacial surgeons, ENT specialists, 
Ophthalmologists, Neurologists, Pathologists, 
Radiologists, Nutritionists, Prosthodontists, Nurses, 
Psychologists, Anaesthetists and Physiotherapists. 
This level of proficiency is scarcely available in many 
urban centres in Africa, and is completely inaccessible 
in rural areas.
 In addition, peak incidences of head and neck 
cancers range from the 5th – 7th decades of life, 
although the incidence in younger age groups is on 
the increase worldwide.  Elderly head and neck cancer 
patients exhibit different clinical characteristics and 
experience different patterns of care from younger 
patients. Effective management of geriatric patients 
with this condition would therefore involve additional 
expenses (11).  It is perhaps due to such logistical 
problems that global five-year survival rates for head 
and neck cancers have remained at 35 – 50% over 
the past three decades despite efforts to improve 
treatment outcomes (12).
 Primary approaches have been emphasised as 
the most cost-effective mode of cancer management. 
However, public health campaigns on the factors 
that contribute to head and neck cancers are almost 
non-existent in the developing world, while habits 
such as cigarette smoking and alcohol consumption 
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continue to increase the incidence of the disease (13). 
Given that HNSCC is a preventable condition, the 
public should be constantly exposed to information 
on methods of risk reduction and early signs of 
disease.  
 Finally, the training and equipping of medical 
personnel should be strategic so as to facilitate the 
functioning of oncology teams in tertiary medical 
centres and teaching hospitals.  In this regard, the 
various medical sub-specialties currently managing 
HNSCC should be commended for the outcomes 
achieved despite the limited resources available. 
Further research and consultation is imperative for 
the development of effective and co-ordinated care 
for head and neck cancer cases in this region. 
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